<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058382</url>
  </required_header>
  <id_info>
    <org_study_id>09-008006</org_study_id>
    <nct_id>NCT01058382</nct_id>
  </id_info>
  <brief_title>Progesterone Support of FET</brief_title>
  <acronym>FETProg</acronym>
  <official_title>Progesterone Support for Frozen Embryo Transfer: Intramuscular Versus Vaginal Suppository - A Prospective, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Coddington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There have been two very common forms of progesterone administration that have been used
      during ovulation induction, in vitro fertilization (IVF) and embryo transfers. There are
      currently no randomized clinical trials to demonstrate which method of progesterone
      administration is more effective for frozen embryo transfer. We raise the question: Is there
      a difference between the two accepted methods of progesterone administration, intramuscular
      and vaginal suppositories, for frozen embryo transfer? Studies for fresh embryo transfer
      after in vitro fertilization, have demonstrated that there is not a difference between the
      two methods of progesterone administration. We will evaluate the question for frozen embryo
      transfer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Frozen Embryo Pregnancy Rate</condition>
  <arm_group>
    <arm_group_label>Progesterone Vaginal Suppositories</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular Progesterone-in-Oil</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone Vaginal Suppositories</intervention_name>
    <description>Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer</description>
    <arm_group_label>Progesterone Vaginal Suppositories</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular Progesterone-in-Oil</intervention_name>
    <description>Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer</description>
    <arm_group_label>Intramuscular Progesterone-in-Oil</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women having a frozen embryo transfer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females &lt; 50 years of age

          -  Having frozen embryo transfer at Mayo Clinic

          -  Embryos have been created prior to age 42

          -  Willing to be randomized to either method of progesterone administration

        Exclusion Criteria:

          -  Diagnosis of severe medical illness

          -  Uterine lesions affecting the cavity or endometrium

          -  Uterine anomaly

          -  Presence of hydrosalpinx

          -  Extreme difficulty with embryo transfer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Coddington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>May 8, 2013</last_update_submitted>
  <last_update_submitted_qc>May 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Charles Coddington</investigator_full_name>
    <investigator_title>Charles C. Coddington MD</investigator_title>
  </responsible_party>
  <keyword>FET</keyword>
  <keyword>Progesterone Support</keyword>
  <keyword>Frozen Embryo Transfer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

